Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04982965 |
| Other study ID # |
Cannabis and Pain |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
Early Phase 1
|
| First received |
|
| Last updated |
|
| Start date |
May 7, 2021 |
| Est. completion date |
March 15, 2027 |
Study information
| Verified date |
January 2024 |
| Source |
University of California, San Diego |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The American Academy of Pain Medicine has labeled pain as a "silent epidemic" due to its
staggering costs to society (over $500 billion/year) and widespread prevalence (affects over
100 million Americans). Thus, it is imperative to test and validate cost-effective pain
therapies.
To this extent, cannabis is characterized as one of the most promising therapies to treat a
wide spectrum of pain conditions. However, the clinical applicability of cannabis-based pain
therapies has been limited due to lacking mechanistic characterization in human-focused
studies. Of critical importance, the neural mechanisms supporting cannabis induced pain
relief remain unknown. The primary objective of the proposed pilot study is to identify the
brain mechanisms supporting the direct alleviation of acutely evoked pain through vaporized
cannabis.
Description:
Behavioral (visual analog scale) and neural (cerebral blood flow) effects of a "medium" dose
(5.1% THC by weight; NIDA supply; University of Mississippi) of vaporized cannabis in
response to a well-validated noxious heat stimulation (49°C) and an emerging fMRI perfusion
technique (arterial spin labeling) will be conducted when compared to placebo (<.1%
THC/weight). Cannabis will be self-administered using a portable Volcano vaporizer -a safe
and reliable method of intrapulmonary administration of cannabinoids and the Foltin Uniform
Puff Procedure (FUPP), an established inhalation protocol commonly used in cannabis research
to reduce variability of dosing across subjects.
Duration of Human Involvement Successful completion of the proposed study will include a
total of 2 sessions. Prior to their enrollment potential subjects will first be screened over
the phone to determine if they qualify for the proposed project. There may be up to 2 weeks
between a subject's initial screening and their official enrollment of the study.
A14-day gap between enrollment and the first experimental session will be provided time to
enroll cohorts, group randomization, and individualized scheduling. Once the schedules have
been determined, the subjects' baseline assessment and baseline testing session will be
scheduled, and a study coordinator(s) will schedule the pharmacologic testing sessions. The
sessions can include weekends; this approach will increase study feasibility, compliance and
adherence.
Planned Data Collection
Data Collection:
The following information will be collected from all subjects: name, date of birth, age,
gender, ethnicity, telephone number email address, handedness, current/previous drug and
cannabis regimen.
All of the proposed procedures are characterized as "experimental".
Study Session 1: Subjects will first report to the ACTRI. After obtaining informed consent,
If subjects are female and of child-bearing age (<55 years), they will be administered a
urine based pregnancy test. Participants will also take a cannabis focused urine screening.
Research technicians will be employed to determine participant eligibility based on our
inclusion and exclusion criteria, including reviewing MRI screening eligibility. These
criteria will simply be based on self-report and assessment of medical history from their
respective physicians, on an "as needed" basis. After meeting study inclusion criteria,
subjects will then be administered and complete one pre-session study questionnaires and will
be trained to reliably use the visual analog scale (VAS) to rate their pain.
Psychophysical Testing
Thermal stimulation: As in all of our prior IRB approved experiments, the MEDOC TSA-II will
be used to deliver all thermal stimuli. All stimulus temperatures will be less than or equal
to 50°C, and volunteers will be free to escape the stimulator at any time. No stimulus will
produce tissue damage. This study will use a 16x16 mm surface area for the delivery of
neutral and noxious stimuli. This modest stimulus area allows a relatively wide range of
noxious stimuli to be delivered (up to 50°C for 30 seconds) without either tissue damage or
significant subject withdrawals/drop-outs. Stimuli in this temperature range have been used
extensively by the PI and numerous laboratories around the world and do not produce tissue
damage or burns. In order to facilitate removal from the stimulator, the stimulator will be
attached to a custom-designed thermal stimulation probe holder. Participants will place their
calf on top of the probe holder and will not be strapped in or otherwise restrained.
Therefore, participants will be able to simply lift their legs at any time.
Cannabis administration
Cannabis will be stored in a locked and alarmed freezer in a UCSD research pharmacy until it
is dispensed to the subjects. Each subject will be provided a lock box in which to store the
capsules assigned to them.
These drugs are not FDA-approved for the proposed subject population and purpose. The IND for
the proposed study is in preparation and will be submitted pending IRB approval.
Study Drug: Bulk cannabis from the following NIDA batches will be purchased from the NIDA
supply at the University of Mississippi. The cannabis supply from NIDA/University of
Mississippi varies in the exact percentages available from year to year. Numerous past
UCSD/CMCR studies have used the NIH/NIDA supply.
1. THC dominant (THC ~5.1%, CBD <0.1%, "THC")
2. Placebo cannabis (THC <0.1%, "Placebo")
Study treatments will be administered under direct observation by a study nurse using a
cued-inhalation procedure. Subjects will be given verbal instructions prior to initiation of
the procedure. The respective dose of cannabis or placebo will be aerosolized using the
VOLCANO-System-Vaporizer (VSV). The VSV releases the active ingredients of the cannabis
through vaporization by hot air. The vapor with active ingredients of the cannabis are
trapped in a bag. A mouthpiece attached to the bag allows for inhalation. The subject will be
seated in a chair in the designated smoking room (in the ACTRI) and will be given the bag
containing aerosolized cannabis. The study nurse/research technician will provide verbal cues
from an adjacent room. The nurse will instruct the subject to inhale for 5 seconds. The
subject will then be instructed to remove the mouthpeice from the lips and hold the
inhalation for 5 seconds (if possible). Next, the subject will be instructed to exhale fully.
The subject will be given a 40-second resting period until the process is repeated up to 3
more times, at which time it is expected that the cannabis content of the bag will be fully
depleted.
Only study physicians, research pharmacist and the research coordinator will be able to
identify the cannabis dosage. This will be a double blinded study.
Experimental Sessions: All of the proposed procedures are characterized as "experimental".
Session 1: This session will serve as the baseline control.
- Subjects will first report to the Altman Clinical and Translational Research Institute
(pressurized clinical room).
- After obtaining informed consent, research technicians will confirm participant
eligibility based on our inclusion and exclusion criteria. Then, if female participants
are of child-bearing age, they will be administered a urine-based pregnancy test.
- Weight will be measured to identify the appropriate drug dosage
- Once eligibility criteria review is complete, the research technician will begin the
psychophysical training and baseline pain testing portion of the session.
- Participants will be trained to reliably use the visual analog scale (VAS) to rate their
pain and introduced to the thermal stimuli. Participants will be familiarized with 32,
5s duration stimuli (35 - 49°C) using the MEDOC TSA-II and use of the VAS. Stimuli will
be delivered to the back of the right calf as subjects lie in supine.
- Baseline psychophysical responses to noxious heat will be assessed by administering a
total of four heat series. Heat series (4min and 24s) include ten, alternating 12s
plateaus of 49°C and 35°C stimulation to the back of the right calf. The thermal probe
will be moved to a different region on the back of the right calf after completion of
the first heat series. VAS pain intensity and unpleasantness ratings will be collected
after each series.
- In the first two heat series, subjects will be instructed to "try to stay still".
Patients will then instruct them to sit quietly for 10 minutes to control for the time
elapsed in the subsequent heat testing-fMRI experimental sessions (Experimental Session
2 ).
- After 10 minutes pass, two heat series will be administered.
- After successful completion of sensory testing, participants will then complete study
questionnaires (see Questionnaires for Study Assessments).
- Randomization will occur after successful completion of study session 1.
Participant Randomization:
Randomization will be tracked in the Screening/Enrollment Log that is maintained by the study
coordinator(s). Randomization will be stratified so that each sex will have their respective
list of randomization codes.
Males and females will be randomized without replacement across a block of 120 codes
(assuming 20% attrition) using an Excel-based random number generator. Subjects will then be
randomized to one of two groups (5% THC/weight vs. <.1% THC/weight). The study coordinator is
responsible for enrolling, scheduling, and randomizing subjects.
Group randomization
THC 5.1% group • Fifty subjects will receive a "medium" dose (5.1% THC by weight; NIDA
supply; University of Mississippi) of vaporized cannabis
THC .1% placebo group
• Fifty subjects will receive a "very low" dose (<.1% THC by weight; NIDA supply; University
of Mississippi) of vaporized cannabis
The following procedures will be performed in each group, respectively.
Session 2: After at least 2 days have elapsed, subjects will report back to the ACTRI to
complete study session 2. Data collection in this session will take no more than 1.5 hour to
complete.
- A research technician will greet subjects as they arrive to the ACTRI and guide them to
the pressurized room.
- ACTRI nurses will then administer a cannabis based drug screening.
- Weight will be measured to confirm the prescribed drug dosage.
- Next, the research technician will issue study assessments to the subject (via REDCap).
- Subjects will then be positioned in the scanner.
- A respiratory transducer will be fitted across the chest.
- Rest: Subjects will be instructed to keep their eyes closed and to reduce movement.Heat
series (4min and 24s) that contain ten, alternating 12s plateaus of 49°C and 35°C
stimulation to the back of the right calf. Two heat series will be administered during
fMRI acquisition. VAS pain intensity and unpleasantness ratings are collected after each
series. The thermal probe will be moved to a different location of the right calf after
each heat series to reduce potential habituation and sensitization. Subjects will be
instructed not to move and to keep their eyes closed.
- Vaporized cannabis administration: Subjects will then be escorted to a pressurized room
in the ACTRI. Subjects will be administered vaporized cannabis by inhaling aerosolized
cannabis through the Volcano vaporizer. The study nurse/research technician will provide
verbal cues from an adjacent room. The nurse will instruct the subject to inhale for 5
seconds. The subject will then be instructed to remove the mouthpeice from the lips and
hold the inhalation for 5 seconds (if possible). Next, the subject will be instructed to
exhale fully. The subject will be given a 40-second resting period until the process is
repeated up to 3 more times and/or until the content of the bag is fully depleted.
- After 10 minutes of cannabis administration, will reposition said subject in the MRI
Scanner.
- Two more heat series will be administered during fMRI acquisition. VAS ratings will be
assessed after each heat series.
- A structural scan will be accrued.
Outcome Measure(s):
1. Cerebral blood flow (average blood perfusion; mL blood/100 grams tissue/minute): changes
in cerebral blood flow (CBF) will be assessed during arterial spin labeling and BOLD
fMRI.
2. Visual Analog Scale (VAS): Pain ratings will be assessed in response to the noxious heat
stimulation. Pain intensity and unpleasantness ratings will be assessed with a Visual
Analog Scale. The minimum rating ("0") is designated as "no pain" whereas the maximum
("10") is labeled as "most intense imaginable" or "most unpleasant imaginable." Higher
numbers correspond to higher pain.
3. Respiration Rate (Biopac respiratory transducer): Changes in respiration rate could be
predictive of analgesia and health promotion.
Questionnaires for Study Assessments:
All questionnaires will be delivered using the Research Electronic Data Capture (REDCap)
platform on iPAD tablets administered and supervised by study personnel. The
questionnaires to be presented on the REDCap platform include the following:
4. Profile of Mood States Questionnaire (POMS-short form): This is a 40-item measure of 6
mood states: tension-anxiety, depression-dejection, anger-hostility, vigor-activity,
fatigue-inertia, and confusion-bewilderment. This assessment is recommended by the
IMMPACT group as a core measure of emotional functioning.
5. Subjects' Global Impression of Change (PGIC): This is a self-report assessment
recommended to evaluate self-reported perception of improvement over trial/efficacy of
treatment.
6. PROMIS 29-Item Profile: This is a 29-item generic health-related survey that assesses
the following 7 domains: depression, anxiety, physical function, pain interference,
fatigue, sleep disturbance, and ability to participant in social roles/activities.
7. State Anxiety Inventory (SAI): The SAI is a prominent 20-item measure for anxiety, and
will be utilized as a manipulation check for our behavioral interventions.
8. SF-12 Health Survey (SF-12): This is a 12-item version of the SF-36 item Health Survey
designed to assess general mental and physical functioning, and overall health-related
quality of life.
9. Beck Depression Inventory (BDI): This is a 21-item standard assessment widely used to
measure clinical depression.
10. Pittsburgh Sleep Quality Index (PSQI): This is a 10-item assessment designed to measure
quality of sleep.
11. Cohen Perceived Stress Scale (PSS): This assessment is critical for controlling stress
in our analyses as well as a potential predictor in clinical pain improvements
12. Positive and Negative Affect Scale (PANAS): This is a 20-item self-report assessment
used to assess positive and negative affect in a subject.
13. UNCOPE: This is a 6-item scale that provides a simple and quick means of identifying
risk for abuse and dependence for alcohol and other drugs
14. Cannabis Use Disorders Identification Test (CUDIT): screens for current cannabis use
disorders (abuse or dependence) according to DSM-IV
15. Problematic Use of Marijuana (PUM): measures ICD-10 harmful use along with problems in
interpersonal relationships and psycho-physical functioning.
16. Cannabis Abuse Screening Test (CAST) identifies patterns of cannabis use leading to
negative consequences on a social or health level for the user himself or others.
17. Bowdle questionnaire: This questionnaire evaluates 3 psychedelic effects (drug high,
alterations in internal perception, and alterations in external perception) from 13
questions scored on a 100-mm visual analogue scale (from 0, no effect, to 100, maximum
effect). Internal perception reflects inner feelings that do not correspond with the
reality and is derived from questions regarding the hearing of unrealistic voices or
sounds and having unrealistic thoughts and paranoid or anxious feelings. The external
perception indicates a misperception of an external stimulus or change in the awareness
of the subject's surroundings and is derived from questions regarding the perceptual
change of body parts, the change of surroundings, the altered passing of time, the
difficulty of controlling thoughts, and the change in color and sound intensity.
Sample Size Determination & Power:
At this stage, the proposed study is exploratory in nature. Neverthelesss, random effects
models require a sample of 15 - 20 participants per group to attain sufficient statistical
power to detect a large effect size in fMRI-based regression models. Sample sizes of 15-16
(per group) can reliably detect the neural correlates of pain relief across multiple fMRI
testing points. However, since individual differences in pain sensitivity and between group
comparisons could decrease the power to assess relatively small differences in neural
activation across time, 100 participants (50 per group) will be recruited to test study
hypotheses. The data collected in this pilot study will also be used to estimate the effect
sizes to help design a larger fully-powered follow-up trial.
Data Analyses and Interpretation:
Age and sex will be entered as covariates if there are between group differences in all
appropriate analyses. As previously, VAS pain intensity and unpleasantness ratings will be
examined in separate analyses. To test study hypotheses, a 2 (group: medium dose vs. placebo)
X 2 (rest vs. cannabis/placebo) repeated measures (RM) ANOVA will be employed. Post-hoc
paired samples t-tests (in each group) will be conducted to test significant main effects and
interactions on behavioral and neural responses. Pain ratings derived from Session 1 may be
entered as covariates. Between groups differences on exploratory outcomes (psychological
assessments) will be assessed with a 2 (group) X 2(pre vs. post) RM ANOVA.
Inclusion of Women and Minorities: Subjects will include all sexes and races. Over 2500
subjects will be recruited from the ACTRI's recruitment service, 11 separate providers, and
the local community. Based on prior work, recruitment will target to recruit 54% Non-Hispanic
White, 15% Non-Hispanic Black, 17% Hispanic, 7% Asian/Pacific Islander, 1% Native
American/American Indian, and 6% Other. If necessary to obtain minority representation,
under-represented racial groups will be targeted specifically for recruitment.
General Considerations:
Data for all individual subjects randomized or exposed to study drug will be presented in
data listings. Continuous data will be summarized using the following descriptive summary
statistics: the number of subjects (n), mean, standard deviation (SD), standard error (SE),
median, minimum value (min), and maximum value (max). Categorical data will be summarized
using counts and percentages.
